These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37340883)

  • 41. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
    Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
    Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
    Cui Q; Hu Y; Ma D; Liu H
    Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bronchial Fistula: Rare Complication of Treatment with Anlotinib.
    Deng P; Hu C; Li Y; Cao L; Yang H; Li M; An J; Jiang J; Gu Q
    Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):858-865. PubMed ID: 32987493
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review.
    Cheng K; Liu X; Chen Y; Zhou K; Li Z
    BMC Gastroenterol; 2022 Aug; 22(1):388. PubMed ID: 35978277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient.
    Li C; Li W; Dai S; Sharma A; Sharma HS; Wu Y
    Prog Brain Res; 2021; 265():407-414. PubMed ID: 34560927
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial.
    Huang NS; Wei WJ; Xiang J; Chen JY; Guan Q; Lu ZW; Ma B; Sun GH; Wang YL; Ji QH; Wang Y
    Thyroid; 2021 Dec; 31(12):1808-1813. PubMed ID: 34610756
    [No Abstract]   [Full Text] [Related]  

  • 48. Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report.
    Wu G; Huang J; Lin L; Yan S; Pan W; Chen Q; Wu X; Lv D
    Immunotherapy; 2022 Sep; 14(13):1007-1013. PubMed ID: 35852100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma: A case report and review of the literature.
    Liu L; Wang X; Wu WB; Zhang M
    Medicine (Baltimore); 2020 Oct; 99(41):e22707. PubMed ID: 33031343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical efficacy of anlotinib plus S-1 as a second-line therapy for recurrent or metastatic esophageal squamous cell carcinoma].
    Sun W; Zou X; Zhang W; Hu S; Ge K
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Feb; 41(2):250-255. PubMed ID: 33624599
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Posterior reversible encephalopathy syndrome associated with use of anlotinib to treat squamous cell carcinoma of the cervix: case report and literature review.
    Lin J; Chen W; Zhong S; Qian K; Chen H; Lin L
    Front Pharmacol; 2023; 14():1255785. PubMed ID: 38169843
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.
    Wang W; Shao L; Xu Y; Song Z; Lou G; Zhang Y; Chen M
    BMC Pulm Med; 2022 May; 22(1):179. PubMed ID: 35524294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complete remission of advanced and recurrent cervical cancer with pembrolizumab treatment- 3 case reports.
    Tung HJ; Wang CC; Liu FY; Lai CH
    Taiwan J Obstet Gynecol; 2021 Sep; 60(5):938-941. PubMed ID: 34507680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pneumothorax in lung cancer following anlotinib treatment: A case report.
    Yang L
    Medicine (Baltimore); 2022 Jul; 101(29):e29273. PubMed ID: 35866828
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world Efficacy Data on Anti-Angiogenic Drugs in Recurrent Small Cell Cervical Carcinoma: A Retrospective Study.
    Qiu H; Su N; Yan S; Li J
    Technol Cancer Res Treat; 2023; 22():15330338231160393. PubMed ID: 36883253
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative Clinical Efficacy of 'Concurrent Chemoradiotherapy (CCRT) and Anlotinib' Than CCRT in Patients with Locally Advanced ESCC.
    Wang G; Beeraka NM; Xiao W; Zhang Y; Xue N; Chen G; Liu J; Liu Y
    Technol Cancer Res Treat; 2022; 21():15330338221080939. PubMed ID: 35235470
    [No Abstract]   [Full Text] [Related]  

  • 58. Case report: the dissociated response and clinical benefit of primary leiomyosarcoma of the bone treated with penpulimab plus lenvatinib after failed multi-line therapy.
    Wang B; Han Y; Liu J; Zhang X; Zhuo H; Jiang Y; Deng Y
    Front Pharmacol; 2023; 14():1239699. PubMed ID: 38026935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report.
    Wang J; Li X; Zhou J; Qiu D; Zhang M; Sun L; Li SC
    Front Oncol; 2023; 13():1043244. PubMed ID: 37091182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report.
    Fu Y; Liu J; Jiang Y
    Front Endocrinol (Lausanne); 2022; 13():810747. PubMed ID: 35399948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.